Biomay – discovery, research and development of innovative allergy therapeutics.
The privately held company pioneers the diagnostic and therapeutic use of recombinant allergens.”

Message from the CEO

Rainer HenningDear Visitor:

This summer again has brought some exiting events for Biomay. 

As you can see from the news section, Fresenius Medical Care is launching an innovative medical device (IgEnio®) for the treatment of IgE mediated diseases shortly. We strongly believe that this treatment will bring new hope to patients with severe asthma, atopic dermatitis or other allergic diseases, who currently have very few treatment options.

 This launch is very significant for Biomay, since the product was co-developed with us, and it contains our single-chain antibody fragment (BM10) as ligand. This highly potent antibody was discovered in Vienna in cooperation with Prof. Rudolf Valenta at the Medical University; Biomay holds the patent rights. Our manufacturing team has successfully developed an efficient and scalable manufacturing process for BM10, which will be the basis for commercial production. We have been able to produce the amount of material required for the impending market launch under strict GMP conforming conditions.

This brings me to the second important event: Following a rigorous GMP inspection by the Austrian health authority AGES, we have been informed that we now receive a permanent GMP certificate for manufacturing of products for clinical development in phases 1-3. This enhances our contract manufacturing offering significantly.

We currently experience a strong demand for our GMP manufacturing services for plasmid DNA. This is in connection with the resurgence of gene therapy, which has made headlines over the last year. We benefit from the fact that we are one of just a handful of manufacturers world-wide with this capability in the lot sizes required for gene therapy approaches. If you are working for a company developing gene therapy products in the clinic, we would love to talk to you!

Finally, please visit our allergen web shop, as we have launched some additional products in our line-up of recombinant allergen proteins. A number of further launches are planned in the near future!

Best regards

Rainer Henning
Chief Executive Officer

Latest News

Fresenius Medical Care releases new adsorber IgEnio® in Europe for treatment of severe allergic symptoms ( 3 Sep. 2015)

Fresenius Medical Care has released a new single-use adsorber for the treatment of IgE...


go to news archive